We use your registration to provide content in a way in which you have given your consent and in our understanding of you. This would possibly come with our and third-party advertisements based on our understanding. You can unsubscribe at any time. More information
The antibodies were separated from the immune formulas of COVID-19 patients recovered by immunologist Dr. Natalia Freund of Tel Aviv University in Israel and her colleagues. of the pandemic. In this research, the researchers sequenced all cells of the B immune formula from the blood of other people in Israel who had recovered from the original variant of SARS-CoV-2, and isolated nine antibodies produced through the patients’ immune formulas. .
It turns out that some of those antibodies are effective in neutralizing the Delta and Omicron variants of Covid.
Dr Freund explained: “In the previous study, we showed that the other antibodies that are formed in reaction to infection with the original virus are targeted in opposite ways to other sites of the virus.
“The most effective antibodies were those that bind to the spike protein of the virus, in the same position in which the tip binds to the mobile receptor ACE2.
“Of course, we were not the only ones to isolate those antibodies, and the global health formula made extensive use of them until the arrival of the various variants of the coronavirus, which rendered those antibodies useless as much as possible. “
In the new study, the team found that two other antibodies, known as TAU-1109 and TAU-2310, bind to the viral spike protein in another of most other antibodies, a fact that made them less effective compared to the original Covid variant.
On the one hand, this makes them very effective at neutralizing the Delta and Omicron variants.
Dr Freund said: “According to our findings, the efficacy of the first antibody, TAU-1109, in Omicron neutralisation is 92% and in DeltaArray neutralisation 90%.
“The momentary antibody, TAU-2310, neutralizes the Omicron variant with an 84% potency and the Delta variant with a 97% potency. “
READ MORE: Covid: new strains imaginable in winter as UK launches withdrawal campaign
Dr. Freund believes that the unexpected effectiveness of those two antibodies may be similar to the evolution of the virus.
He explained: “The infectivity of the virus is greater with the variant because, over time, it changed the amino acid series of the spike protein component that binds to the ACE2 receptor, thus expanding its infectivity and at the same time avoiding the herbal antibodies that were created after vaccines.
“In contrast, the tau-1109 and TAU-2310 antibodies do not bind to the ACE2 receptor binding, but to some other region of the spike protein, a viral tip domain that, for some reason, does not go through many mutations.
“So, they’re effective at neutralizing more viral variants. These findings were obtained when we tested all known strains of COVID to date. “
These tests, the researchers explained, were performed against viruses living in laboratory cultures and pseudoviruses, substitutes usually created by combining proteins discovered on the surface of a virus with the central genome of some other virus deactivated.
NOT TO BE MISSED: EU crisis erupts: Bloc is in CHAOS as countries rage over VDL plans [INSIGHT] An energy lifeline like Rees-Mogg provides a prime seasoning all the way to Britain’s North Sea [REPORT] Energy: Truss bypassed a master plan to CANCEL same-day bill value limit a [ANALYSIS]
Dr. Freund believes that this discovery of antibodies will enable a “real revolution” in the fight against COVID-19.
He added: “We want to take a look at the COVID-19 pandemic in the context of past outbreaks that humanity has witnessed.
“People who were vaccinated against smallpox at birth and are now 50 years old still have antibodies, so they are protected, at least partially, from the monkeypox virus that we’ve been hearing about recently.
“Unfortunately, this is not the case with the coronavirus. For reasons we still don’t fully understand, the level of antibodies to COVID-19 drops drastically after 3 months, so we see other people becoming inflamed again and again, even after being vaccinated 3 times.
Dr Freund concluded: “From our point of view, targeted antibody treatment and delivery to the frame at peak concentrations can serve as an effective replacement for repeated withdrawals, especially for at-risk populations and those with weakened immune systems.
“COVID-19 infection can cause serious illness and we know that offering antibodies on the first day after infection can prevent the spread of the virus.
“Therefore, it is conceivable that by employing effective antibody therapy, we may not have to deliver booster doses to the entire population every time there is a new variant. “
The full effects of the were published in the journal Communications Biology.